Printer Friendly

BRISTOL-MYERS SQUIBB PHARMACEUTICAL

 PRINCETON, N.J., April 20 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the appointment of Gary King, Ph.D., to the position of licensing director, Europe, for the Pharmaceutical Group.
 In his new position, King will be responsible for evaluating new investment, development and marketing opportunities throughout Europe in support of the Pharmaceutical Group's research and commercial objectives.
 Prior to this new appointment, King served as director, Commercial Development, Americas for the Bristol-Myers Squibb Pharmaceutical Group. He joined the company in 1987 as associate director of Licensing and in 1989, he was appointed director of Licensing.
 Before joining Bristol-Myers Squibb, King held research positions with Ayerst Laboratories Research and Bio-Research Laboratories in Canada. He holds a B.S. in psychology from Wayne State University, and an M.A. and Ph.D. from the University of Toronto. Among his achievements is the 1980 Canadian Medical Research Council's Postdoctoral Fellowship.
 King lives in Langhorne, Pa.
 /delval/
 -0- 4/20/93
 /CONTACT: Peggy Ballman of Bristol-Myers Squibb, 609-252-5323/
 (BMY)


CO: Bristol-Myers Squibb Company ST: New Jersey IN: MTC SU: PER

MK-LJ -- PH020 -- 7989 04/20/93 11:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 20, 1993
Words:187
Previous Article:WEAN INCORPORATED REPORTS 1993 FIRST QUARTER RESULTS AND PROGRESS ON RESTRUCTURING
Next Article:LOUISIANA-PACIFIC COMPLETES BEST QUARTER EVER
Topics:


Related Articles
BRISTOL-MYERS SQUIBB TO INTRODUCE PRAVACHOL, CHOLESTEROL-LOWERING AGENT
BRISTOL-MYERS SQUIBB PROMOTES WEG TO GROUP PRESIDENT
BRISTOL-MYERS SQUIBB COMPANY PROMOTES SPECIALTY PHARMACEUTICALS EXECUTIVE
BRISTOL-MYERS SQUIBB COMPANY PROMOTES LEGAL EXECUTIVE
BRISTOL-MYERS SQUIBB COMPANY AND N.J. GOV. FLORIO CELEBRATE DEDICATION OF NEW COMPLEX IN PLAINSBORO, N.J.
BRISTOL-MYERS SQUIBB TAKES EQUITY POSITION IN IXSYS -- WILL FUND THREE-YEAR R&D PROGRAM
ALTEON INC. APPOINTS FORMER BRISTOL-MYERS SQUIBB EXECUTIVE JAMES J. MAUZEY AS CHIEF EXECUTIVE OFFICER
CYTOGEN ELECTS BRUCE R. ROSS TO BOARD OF DIRECTORS
EU'S CPMP GIVES NEW HIV THERAPY POSITIVE OPINION ZERIT (STAVUDINE, D4T)FOUND TO HAVE CLINICAL BENEFIT VERSUS CONTINUED AZT
Bristol-Myers Squibb and Karo Bio Enter Collaboration; Partnership to Develop New Treatments for Obesity and High Cholesterol

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters